TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the year ended December 31, 2024 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) un ...

CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, May 9, 2025, at 8:00 a.m. MT / 10:00 a.m. ET. The conference call may be accessed by dial in or via webcast: Pre-register for the Conference Call:https://dpregister.com/sreg/10199336/ff099f3 ...

Core Insights - ROHM Semiconductor's latest 2kV SiC MOSFETs have been adopted by SMA Solar Technology AG for their new power conversion solution "Sunny Central FLEX" [1][2] - The collaboration between ROHM, Semikron Danfoss, and SMA aims to enhance grid connections for photovoltaic installations and battery storage systems [1][4] Company Overview - SMA Solar Technology AG is a leading global specialist in photovoltaic and storage system technology, providing a range of high-efficiency PV and battery inverters, energy management systems, and charging solutions for electric vehicles [5][6] - Semikron Danfoss is a global technology leader in power electronics, focusing on semiconductor devices and power modules for automotive, industrial, and renewable energy applications [7][8] - ROHM is a prominent semiconductor and electronic component manufacturer, supplying a variety of components across multiple sectors, including automotive and industrial equipment [9][10] Product Details - The new 2kV SiC MOSFETs are designed for high reliability and efficiency, suitable for 1500V DC links, and are already in mass production [2][3] - The SEMITRANS 20 module, developed by Semikron Danfoss, incorporates ROHM's SiC MOSFETs and is tailored for high power applications, including solar and energy storage inverters [3][4] Environmental Impact - SMA's inverters have contributed to preventing over 64 million tons of CO2 emissions globally, showcasing the environmental benefits of their technologies [6]

Greenville, South Carolina, April 28, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to report that it has filed its 2024 year end, audited Financial Statements and related Management Discussion and Analysis as summarized below. The Company also reports the appointment of Adam Ho as interim Chief Financial Officer, effective May 1, 2025. Mr. Ho will succeed Jason Tong, who will continue to serve as the Company’s Controller. Mr. Ho also serves as a Director of ...

MEMPHIS, Tenn., April 28, 2025 (GLOBE NEWSWIRE) -- AutoZone, Inc. (NYSE: AZO), the leading retailer and distributor of automotive replacement parts and accessories in the Americas, will release results for its third quarter ended Saturday, May 10, 2025, before market open on Tuesday, May 27, 2025. Additionally, the Company will host a one-hour conference call on Tuesday, May 27, 2025, beginning at 10:00 a.m. (ET), to discuss the results of the quarter. This call is being webcast and can be accessed, along w ...

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Finning International Inc. (TSX: FTT) (“Finning”) will report Q1 2025 results on May 12, 2025 after markets close and hold the investor call on May 13, 2025 at 10:00 AM Eastern Time. To access the investor call, please dial 1-833-752-3398 (Canada and US toll free) or 1-647-846-2852 (international toll). The investor call will be webcast live and archived for three months. Please visit our website to access the webcast and accompanying presentat ...

Group 1 - Volatus Aerospace Inc. is conducting a non-brokered private placement of up to 16,666,667 units at a price of $0.12 per unit, aiming for gross proceeds of up to $2,000,000.04 [1][4] - Each unit consists of one common voting share and one common share purchase warrant, with the warrant allowing the purchase of one common share at an exercise price of $0.20 for 36 months [2] - The net proceeds from the financing will be allocated for capital expenditures, inventory, and general corporate and working capital purposes [3] Group 2 - The financing is expected to close on or before May 9, 2025, subject to customary conditions and regulatory approvals [4] - The company may pay eligible finders a cash fee of up to 8% of the gross proceeds from the financing [4] - The offering is being conducted under the Listed Issuer Financing Exemption, meaning securities issued to Canadian residents will not be subject to a hold period [6] Group 3 - Volatus Aerospace is recognized for its innovative global aerial solutions, serving various industries including oil and gas, energy utilities, healthcare, public safety, and infrastructure [8] - The company focuses on enhancing operational efficiency, safety, and sustainability through advanced aerial technologies [8]

Core Insights - TScan Therapeutics, Inc. announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, highlighting its focus on TCR-engineered T cell therapies for cancer treatment [1][2]. Company Overview - TScan is a clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed to prevent relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets across multiple HLA types, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Presentation Details - The poster presentation titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation" will take place on May 13 from 6:00 - 7:30 p.m. Central Time [2]. - The presentation will be held in the Poster Hall, Hall I2, and materials will be available on the company's website post-presentation [2].

Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5- ...

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for ...